Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 1/20 | 0.30 |
| ▸ | GABRD | O14764 | 1/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.30 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.30 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.30 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.30 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.30 |
| ▸ | GABRE | P78334 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.30 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.30 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.30 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8021751 | 1.00 | GABRP (0.30) | GABRPGABRDGABRA1TSHRGABRB1 | |
| SCHEMBL596950 | 1.00 | GABRP (0.30) | GABRPGABRDGABRA1TSHRGABRB1 | |
| SCHEMBL6865407 | 0.87 | MCL1 (0.34) | — | |
| SCHEMBL7720880 | 0.75 | CYP1A2 (0.35) | — | |
| SCHEMBL9184577 | 0.73 | — | — | |
| SCHEMBL1069345 | 0.70 | — | — | |
| SCHEMBL5516725 | 0.70 | — | — | |
| SCHEMBL13740138 | 0.67 | SIRT1 (0.31) | — | |
| SCHEMBL6622419 | 0.65 | — | — | |
| SCHEMBL28003100 | 0.65 | EDNRB (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411492-A1 | ANTIBODY AGAINST CLAUDIN 18A2 AND USE THEREOF | QILU PHARMACEUTICAL CO., LTD. (CN) | 2022-12-29 | — | — | US | claimed |
| WO-2022144780-A1 | SULFONAMIDE DERIVATIVES, COMPOSITIONS COMPRISING SAME AND USES THEREOF IN THE TREATMENT OF CANCERS | NATIONAL CANCER CENTER (JP) | 2022-07-07 | — | — | WO | claimed |
| WO-2022100590-A1 | ADCC-ENHANCED HUMANIZED ANTIBODY FOR CLAUDIN 18A2 AND APPLICATION THEREOF | 齐鲁制药有限公司 | 2022-05-19 | — | — | WO | claimed |
| EP-3971208-A1 | ANTIBODY AGAINST CLAUDIN 18A2 AND USE THEREOF | QILU PHARMACEUTICAL CO., LTD. (CN) | 2022-03-23 | — | — | EP | claimed |
| US-12622891-B2 | AMP-activated protein kinase activator | KYOTO PHARMACEUTICAL UNIVERSITY (JP) | 2026-05-12 | — | — | US | disclosed |
| EP-3868384-B1 | CYCLIC DINUCLEOTIDES AS STING (STIMULATOR OF INTERFERON GENES) AGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2026-02-25 | — | — | EP | disclosed |
| US-12415853-B2 | Antibody against claudin 18A2 and use thereof | QILU PHARMACEUTICAL CO., LTD. (CN) | 2025-09-16 | — | — | US | disclosed |
| US-12414934-B2 | Combination therapies | Aardvark Therapeutics, Inc. (US) | 2025-09-16 | — | — | US | disclosed |
| US-20250262298-A1 | STING MODULATOR COMPOUNDS WITH SULFAMATE LINKAGES, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-08-21 | — | — | US | disclosed |
| US-20250205270-A1 | ANTIBODY-DRUG CONJUGATE PRECURSORS COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-06-26 | — | — | US | disclosed |
| US-12329739-B2 | Isoflavonoid compounds and methods for the treatment of cancer | Aardvark Therapeutic, Inc. (US) | 2025-06-17 | — | — | US | disclosed |
| US-12318364-B2 | Isoflavonoid compositions and methods for the treatment of cancer | Aardvark Therapeutics, Inc. (US) | 2025-06-03 | — | — | US | disclosed |
| WO-2007014934-A2 | QUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007014941-A2 | QUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007014940-A2 | QUINOLINE DERIVATIVES AS ANTIBACTERICAL AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007000435-A1 | QUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007000434-A1 | QUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007000436-A1 | QUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-01-04 | — | — | WO | disclosed |
| WO-2006131519-A1 | QUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-14 | — | — | WO | disclosed |
| US-20060281741-A1 | Quinoline derivatives as antibacterial agents | JANSSEN-CILAG (FR) | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12414934-B2 | Combination therapies | PCK2, PDK1, PCK1 | GABRP 2371/4885GABRD 3644/4885GABRA1 3980/4885 |
| US-20250262298-A1 | STING MODULATOR COMPOUNDS WITH SULFAMATE LINKAGES, AND METHODS OF MAKING AND USING | STING1, CGAS, TBK1 | GABRP 1454/4885GABRD 1917/4885GABRA1 1517/4885 |
| US-20060281741-A1 | Quinoline derivatives as antibacterial agents | HRH1, HRH2, HAO1 | GABRP 1937/4885GABRD 1466/4885GABRA1 1092/4885 |
| US-12318364-B2 | Isoflavonoid compositions and methods for the treatment of cancer | BAX, CASP3, SI | GABRP 1561/4885GABRD 2868/4885GABRA1 3818/4885 |
| US-12622891-B2 | AMP-activated protein kinase activator | PRKAA1, PRKAG1, PRKAB1 | GABRP 2540/4885GABRD 4019/4885GABRA1 3679/4885 |
| US-20250205270-A1 | ANTIBODY-DRUG CONJUGATE PRECURSORS COMPRISING A CYCLIC DINUCLEOTIDE | STING1, CGAS, TLR9 | GABRP 1785/4885GABRD 2341/4885GABRA1 1257/4885 |
| US-12329739-B2 | Isoflavonoid compounds and methods for the treatment of cancer | BAX, CASP3, API5 | GABRP 3239/4885GABRD 4078/4885GABRA1 4391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.